← Every applicant
Ipca Labs Ltd FDA Approvals
17 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| AMLODIPINE BESYLATENew drugSep 22, 2026TABLET, ORAL |
| PROPRANOLOL HYDROCHLORIDENew drugMay 1, 2026CAPSULE, EXTENDED RELEASE, ORAL |
| SUMATRIPTAN SUCCINATENew drugJul 15, 2025TABLET, ORAL |
| METOPROLOL SUCCINATENew drugJun 25, 2025TABLET, EXTENDED RELEASE, ORAL |
| BUPROPION HYDROCHLORIDENew drugMay 2, 2025TABLET, EXTENDED RELEASE, ORAL |
| CHLORTHALIDONENew drugNov 12, 2024TABLET, ORAL |
| ETODOLACNew drugAug 1, 2024CAPSULE, ORAL |
| RISPERIDONENew drugJun 26, 2024TABLET, ORAL |
| ALENDRONATE SODIUMNew drugJun 4, 2024TABLET, ORAL |
| GABAPENTINNew drugMay 29, 2024TABLET, ORAL |
| IRBESARTANNew drugMay 22, 2024TABLET, ORAL |
| QUETIAPINE FUMARATENew drugMay 20, 2024TABLET, ORAL |
| LEVOCETIRIZINE DIHYDROCHLORIDENew drugMay 6, 2024TABLET, ORAL |
| ETODOLACNew drugMay 1, 2024TABLET, ORAL |
| ESZOPICLONENew drugDec 29, 2023TABLET, ORAL |
| GABAPENTINNew drugNov 20, 2023CAPSULE, ORAL |
| ONDANSETRONNew drugOct 30, 2023TABLET, ORALLY DISINTEGRATING, ORAL |